Eyevance announced the launch of Tobradex® ST (tobramycin/dexamethasone ophthalmic suspension) 0.3%/0.05% for the treatment of steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists.
Tobradex ST contains tobramycin, an antibacterial drug, and dexamethasone, a potent corticosteroid. It is formulated using proprietary technology designed to enhance bactericidal activity, ocular surface retention time, and improved bioavailability that allows for a reduced concentration of dexamethasone.
Commenting on the approval, Paul M. Karpecki, OD, FAAO, Director, Cornea, Kentucky Eye Institute, said, “Tobradex ST’s exceptional clinical profile makes it a highly attractive treatment option for all forms of blepharitis, conjunctivitis and contact lens acute red eye.”
Tobradex ST is supplied as an ophthalmic suspension containing 3mg/mL of tobramycin and 0.5mg/mL of dexamethasone.
For more information visit eyevance.com.
This article originally appeared on MPR